JDRF Blog

JDRF Blog

Information on research, events, activities, and news from the T1D community across Canada. 

Subscribe to the newsletter

New Quebec registry tracks hypoglycemia among diabetes patients to help reduce risks

Dr. Rémi Rabasa-Lhoret, a JDRF-funded endocrinologist at the Institut de recherches cliniques de Montréal best known for his work on the...

Read More

A JDRF legacy lives on with the Dr. Robert Goldstein Award

A JDRF legacy lives on with the Dr. Robert Goldstein Award

Dr. Esteban N. Gurzov, a talented young scientist from Brussels, Belgium, was recently named the first recipient of JDRF’s Dr. Robert Goldstein Award.


Paying it forward through research: From trial participant to T1D advocate

Paying it forward through research: From trial participant to T1D advocate

From Walk participant to trial participant to T1D advocate, here is Ash Hunkin's story.


JDRF Canada welcomes new Chief Scientific Officer, Dr. Sarah Linklater

JDRF Canada welcomes new Chief Scientific Officer, Dr. Sarah Linklater

We are pleased to announce Dr. Sarah Linklater has been appointed as Chief Scientific Officer (CSO). 


New test offers better insight into genetic risk of type 1 diabetes in people of African descent

New test offers better insight into genetic risk of type 1 diabetes in people of African descent

Recently, a team of researchers in the United States developed a test to identify individuals of African descent who are more likely to get the disease.


Studying the role of Vitamin D in the risk of type 1 diabetes

Studying the role of Vitamin D in the risk of type 1 diabetes

Does Vitamin D play a role in developing type 1 diabetes (T1D)?


Sernova recruits first subjects for its Cell Pouch<sup>TM</sup> diabetes clinical trial

Sernova recruits first subjects for its Cell Pouch diabetes clinical trial

Since 2016, JDRF and Sernova Corp., a clinical-stage regenerative medicine company, have been collaborating on innovative technology to treat hypoglycaemia (low sugar) unawareness in patients with severe T1D.


Drug approved for treatment of psoriasis and Crohn's disease may protect beta cell transplants

Drug approved for treatment of psoriasis and Crohn's disease may protect beta cell transplants

Currently, JDRF-funded researcher, Dr. Jan Dutz, and his team at the University of British Columbia are investigating whether the administration of an antibody called ustekinumab among adults and children newly diagnosed with T1D can protect insulin-producing beta cells.


Exploring oral therapy to safeguard beta cells and treat type 1 diabetes

Exploring oral therapy to safeguard beta cells and treat type 1 diabetes

Administering insulin on a daily basis can be a tedious task, particularly among individuals newly diagnosed with type 1 diabetes (T1D). To mitigate this, researchers are currently experimenting with islet (insulin-producing cells) transplantation as a promising therapy that eliminates the need for ...


#AccessForAll: We're demanding affordable and accessible coverage for everyone living with type 1 diabetes

#AccessForAll: We're demanding affordable and accessible coverage for everyone living with type 1 diabetes

JDRF is excited to be launching our new Access for All campaign this week to urge provincial and territorial governments, insurers and employers to help make life-changing technologies affordable and accessible for Canadians with type 1 diabetes.


Lets turn type one into type none